Bristol-Myers Squibb Company (BMY) Price History:15.28%(TTM)
The price cagr for Bristol-Myers Squibb Company (BMY) is +15.28% over the latest trailing 12-month period. The comparable SPY value is +22.92%. Year-to-date price return is +5.65%. Price CAGR uses adjusted close price history and excludes dividends.
Current Price
$56.48
+$0.91 (+1.64%)
Previous Close: $55.57
Today's Trading
- Open
- $56.03
- Day High
- $56.53
- Day Low
- $55.26
- Volume
- 8.83M
- Avg Volume
- N/A
52-Week Position
69%
of the 52-week price range
- From 52-week high
- -10.19%
- From 52-week low
- +32.83%
52-Week Price Range
52-Week Low
$42.52
Oct 29, 2025
Current Price
$56.48
69% of range
52-Week High
$62.89
Feb 27, 2026
Price Returns by Period
1 Day
+1.64%
7 Days
+3.71%
30 Days
+0.57%
YTD
+5.65%
1 Year
+15.27%
vs 52W High
-10.19%
BMY Price Chart
Long-Term Performance (CAGR)
Price CAGR (3Y)
-4.48%
Price CAGR (5Y)
-2.89%
Total Return CAGR (3Y)
+0.06%
Total Return CAGR (5Y)
+1.10%
CAGR (Compound Annual Growth Rate) shows the annualized return over the specified period. Total Return includes dividends reinvested.
Key Price Statistics
| Current Price | $56.48 |
| Previous Close | $55.57 |
| Day Range | $55.26 - $56.53 |
| 52-Week Range | $42.52 - $62.89 |
| Volume | 8.83M |
| Average Volume | N/A |
| Market Cap | $115.34B |
| % from 52W High | -10.19% |
Related Metrics
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Christopher S. Boerner